Skip to main content
EDSA
NASDAQ Life Sciences

Edesa Biotech CEO Continues Share Accumulation with $42.5K Open Market Purchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.8
Mkt Cap
$30.137M
52W Low
$0.72
52W High
$5.399
52W Position info
428% above low
Off High info
30% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

EDSA has more than doubled off its 52-week low of $0.72.

Summary

Edesa Biotech's CEO, Pardeep Nijhawan, purchased an additional $42,560 in common shares, marking a continued pattern of insider accumulation following positive clinical data.


Key Events · Ownership and Investor Activity · EDSA

  • CEO Open Market Purchase

    CEO Pardeep Nijhawan acquired 10,000 common shares for $42,560 at an average price of $4.26 per share on March 4, 2026.

  • Continued Insider Accumulation

    This marks the third reported open-market purchase by the CEO in the past week, following previous buys of $99,176 on March 2, 2026, and $36,300 on March 4, 2026.

  • Post-Positive Clinical Data

    The purchases follow the company's announcement of positive Phase 3 data for paridiprubart on February 24, 2026.

  • Addressing Going Concern

    The CEO's continued investment signals confidence amidst the company's previously disclosed material uncertainty regarding its ability to continue as a going concern.


Analysis · EDSA · Life Sciences

Edesa Biotech's CEO, Pardeep Nijhawan, has made another open-market purchase, adding $42,560 worth of common shares. This latest transaction, following recent positive Phase 3 data and previous insider buys, reinforces management's confidence in the company's prospects, especially in light of the previously disclosed going concern uncertainty. The repeated accumulation by the CEO suggests a strong belief in the company's value and future despite its financial challenges.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EDSA was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.1M. The 52-week trading range was $0.72 to $5.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EDSA - Latest Insights

EDSA
Nov 17, 2026, 9:25 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $1.99 info
Change: +$0.050 (+3%) info
Market Cap: $27.023M info
EDSA
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $1.99 info
Change: -$0.360 (-15%) info
Market Cap: $27.023M info
EDSA
Nov 09, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $1.99 info
Change: -$0.5382 (-21%) info
Market Cap: $27.023M info
EDSA
Oct 23, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $1.99 info
Change: -$0.780 (-28%) info
Market Cap: $27.023M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $1.99 info
Change: -$0.630 (-24%) info
Market Cap: $27.023M info